arrow
Z

Zarnie Lwin

Royal Brisbane & Women's Hospital
H指数:25
被引数:3,220

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC)-A Phase 1B/2 Trial

POPCORN研究临床结果:非小细胞肺癌(NSCLC)中术前PD1检查点阻滞和NF-κB配体受体激活剂(RANKL)抑制的药效学——一项1B/2期临床试验

2026-01-010
OA
PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading

PATH-18. 研究CDKN2A缺失在IDH突变型胶质瘤中的作用:超越肿瘤分级的生物学见解

2025-11-110
OA
TARGETING EPH FAMILY OF RECEPTORS: ADVANCED PRECISION THERAPY FOR GBM

靶向Eph受体家族:GBM的先进精准疗法

2025-11-010
PRE
Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study

低级别和间级别胶质瘤伞式研究:分子指导疗法(LUMOS2)研究

2025-11-010
OAAI
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
2024-04-171
PRE
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Dec, 10.1007/s11060-023-04513-1, 2023)

对两项前瞻性随机研究的综合分析,探讨延长放疗后替莫唑胺对新诊断胶质母细胞瘤生存结局的影响 (12月,10.1007/s11060-023-04513-1,2023)

2024-01-301
OA
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
2023-12-283
PRE
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma

肉豆蔻: nivolumab和替莫唑胺与替莫唑胺单独治疗新诊断的老年胶质母细胞瘤患者的随机II期研究

2023-09-227
OAAI
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

PF-06747775单药或联合帕博西尼治疗表皮生长因子受体突变型晚期非小细胞肺癌的1b/2期研究

2022-06-036
OA
The dystroglycan receptor maintains glioma stem cells in the vascular niche
2019-08-2819
OAAI